Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17942062 | 0.87 | ADRA1A (0.44) | HTR2BADRA1AALDH1A1ADRA2AF10 | |
| SCHEMBL17942064 | 0.87 | ADRA1A (0.44) | HTR2BADRA1AALDH1A1ADRA2AF10 | |
| SCHEMBL13240711 | 0.79 | JAK1 (0.52) | PBK | |
| SCHEMBL25519932 | 0.79 | JAK1 (0.52) | PBK | |
| SCHEMBL196337 | 0.79 | — | — | |
| SCHEMBL5163454 | 0.77 | ADRA1A (0.46) | HTR2BADRA1AALDH1A1ADRA2ASMN1; SMN2 | |
| SCHEMBL7809418 | 0.76 | ADRA1A (0.52) | HTR2BADRA1AADRA2AF10 | |
| SCHEMBL4585762 | 0.76 | ADRA1A (0.52) | HTR2BADRA1AADRA2AF10 | |
| SCHEMBL16335893 | 0.75 | SMYD3 (0.48) | PBKALDH1A1L3MBTL1GID4SMYD3 | |
| SCHEMBL16335896 | 0.75 | SMYD3 (0.48) | PBKALDH1A1L3MBTL1GID4SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4108663-A1 | SUBSTITUTED ARYL COMPOUND | Simcere Pharmaceutical Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HTR2B 1675/4885ADRA1A 745/4885PBK 3187/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | HTR2B 1042/4885ADRA1A 1407/4885PBK 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.